S
Sunil Nepal
Researcher at Novartis
Publications - 2
Citations - 204
Sunil Nepal is an academic researcher from Novartis. The author has contributed to research in topics: Apixaban & Hazard ratio. The author has an hindex of 2, co-authored 2 publications receiving 194 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation
Lars Wallentin,Renato D. Lopes,Michael G. Hanna,Laine Thomas,Anne S. Hellkamp,Sunil Nepal,Elaine M. Hylek,Sana M. Al-Khatib,John H. Alexander,Marco Alings,John Amerena,Jack Ansell,Philip E. Aylward,Jozef Bartunek,Patrick J. Commerford,Raffaele De Caterina,Çetin Erol,Veli-Pekka Harjola,Claes Held,John D. Horowitz,Kurt Huber,Steen Husted,Matyas Keltai,Fernando Lanas,Liu Lisheng,John J.V. McMurray,Byung Hee Oh,Mårten Rosenqvist,Witold Rużyłło,Philippe Gabriel Steg,Dragos Vinereanu,Denis Xavier,Christopher B. Granger +32 more
TL;DR: The benefits of apixaban compared with warfarin for stroke or systemic embolism, bleeding, and mortality appear similar across the range of centers’ and patients’ predicted quality of international normalized ratio control.
Journal ArticleDOI
Response to letter regarding article, "efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation"
Lars Wallentin,Renato D. Lopes,Michael G. Hanna,Laine Thomas,Anne S. Hellkamp,Sunil Nepal,Elaine M. Hylek,Sana M. Al-Khatib,John H. Alexander,Marco Alings,John Amerena,Jack Ansell,Philip E. Aylward,Jozef Bartunek,Patrick J. Commerford,Raffaele De Caterina,Çetin Erol,Veli-Pekka Harjola,Claes Held,John D. Horowitz,Kurt Huber,Steen Husted,Matyas Keltai,Fernando Lanas,Liu Lisheng,John J.V. McMurray,Byung Hee Oh,Mårten Rosenqvist,Witold Rużyłło,Philippe Gabriel Steg,Dragos Vinereanu,Denis Xavier,Christopher B. Granger +32 more
TL;DR: The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial was a prospective, randomized, clinical trial in which the patients were recruited over more than a year and the follow-up time was predefined to continue until a prespecified number of primary outcome events were accrued.